We are pleased to announce an investment of nearly £1.2 million into new translational research projects aimed at accelerating the development of treatments for brain tumours. Translational research addresses the critical gap between promising laboratory discoveries and their transformation into effective clinical therapies. This gap—commonly referred to as the “translational valley of death”—is especially significant in brain tumour research due to the rarity and complexity of these tumours and the challenges of developing treatments that can cross the blood-brain barrier. These difficulties often result in limited investment from pharmaceutical and biotech companies.
To overcome these obstacles, we launched the Translational Award in 2024, a dedicated funding initiative designed to make early-stage innovations in brain tumour therapeutics, diagnostics, and medical technologies more attractive for further development. For the first time, this award was open to biotech and pharmaceutical companies alongside academic institutions, creating new avenues for collaboration and impact. Through this model, we aim not only to fund the research but also to provide strategic support to help projects succeed.
As a result, three groundbreaking projects have been selected, each receiving up to £400,000. These projects are focused on turning scientific breakthroughs into practical advances in diagnosis, treatment, and care for people living with brain tumours. This initiative marks a significant step in our commitment to closing the gap between the lab and the clinic, offering new hope to patients and their families.
